|Awarded On||February 16, 2022|
|Title||Combination Therapy for Treatment of Sleep Disturbance in Patients with Advanced Cancer|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Sriram Yennu|
|Cancer Sites||All Sites|
The proposed research is relevant to public health because although poor sleep quality is common, severe, and debilitating in patients with advanced cancer, these patients continue to suffer as very few studies have been conducted and there are few effective treatments.
The goal of the study is to investigate the ability of bright light therapy, melatonin, and methylphenidate combined with melatonin to potentiate the effects of cognitive behavioral therapy, a treatment that shows only modest effects alone, for improvement of sleep quality in prior studies in cancer patients. If found to be effective, this novel treatment could have the potential to immediately impact the clinical care of ad...